Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public alert regarding the withdrawal of medicines containing levamisole following safety concerns raised by European regulators. The alert follows a review that linked levamisole to rare but serious neurological complications affecting the brain. NAFDAC is advising healthcare professionals, distributors, and the public to take precautionary measures while reinforcing the importance of medication safety and regulatory monitoring.
Why It Matters To Your Health
For patients, this alert highlights the importance of understanding both the benefits and risks of medications used to treat common conditions such as worm infections. While levamisole has historically been used as a deworming medicine, new safety evidence suggests that it may cause severe neurological complications in rare cases.
The condition of concern, leukoencephalopathy, affects the brain’s white matter, which plays a critical role in communication between different parts of the nervous system. Damage to this area can lead to symptoms such as muscle weakness, speech difficulties, confusion, movement problems, and other neurological impairments.
The alert also matters because safer alternative treatments for parasitic worm infections are available. Regulatory agencies continuously monitor the safety, and when new evidence shows that a medicine’s risks outweigh its benefits, action is taken to protect public health.
What You Can Do
If you have recently used a medicine containing levamisole, do not panic. Serious neurological reactions are considered rare. However, it is important to remain alert for unusual symptoms.
You should:
- Speak with your pharmacist or doctor if you are unsure whether a medicine you used contains levamisole.
- Seek medical attention immediately if you experience muscle weakness, difficulty speaking, confusion, poor coordination, or other unusual neurological symptoms.
- Avoid self-medicating with older or unverified deworming products.
- Purchase medicines only from licensed pharmacies and trusted healthcare providers.
- Follow NAFDAC safety alerts and recommendations regarding medicine use.
Understanding The Issue
Levamisole is a medicine that has been used for many years to treat infections caused by certain parasitic worms. It works by affecting the worms’ nervous systems, causing paralysis and allowing them to be expelled from the body.
The recent safety review focused on reports of leukoencephalopathy and other neurological complications associated with levamisole use. Leukoencephalopathy refers to damage to the white matter of the brain. White matter contains nerve fibers covered by myelin, a protective coating that helps nerve signals travel efficiently throughout the nervous system. When white matter is damaged, communication between different parts of the brain can be disrupted.
One of the major concerns identified during the review was the unpredictable nature of these adverse effects. Cases were reported after a single dose of levamisole, and symptoms sometimes appeared months after treatment. This makes early detection difficult and complicates efforts to identify patients who may be at risk.
Symptoms of levamisole-associated neurological injury may include weakness, difficulty speaking, impaired coordination, confusion, memory problems, and difficulties with movement. In severe cases, the condition can become debilitating or life-threatening if not recognized and treated promptly.
A common misconception is that medicines used for routine conditions such as deworming are always risk-free. While many medicines are generally safe when used appropriately, all medicines can have side effects. This is why ongoing safety monitoring by regulators such as NAFDAC and international agencies remains essential.
The withdrawal recommendation demonstrates how regulatory agencies respond when new evidence emerges. The decision was based on reports of adverse events, scientific literature, expert consultations, and a comprehensive review of available data. According to the review, alternative medicines are available for treating parasitic worm infections, reducing the need to continue using a medicine with potentially serious neurological risks.
When To Speak With A Healthcare Professional
Speak with a pharmacist or doctor if:
- You have recently taken a levamisole-containing medicine.
- You are unsure whether your medication contains levamisole.
- You need advice on alternative treatments for worm infections.
- You develop symptoms such as weakness, speech difficulties, confusion, or movement problems after taking a deworming medication.
Seek urgent medical attention if neurological symptoms are severe, rapidly worsening, or interfere with normal daily activities.
